STP

• CO-049 • CO-049 - Impact of GLCCI1 Genetic Polymorphism (rs37972) on response to Prednisone in giant cell arteritis (PREDICORT study) > V. Venceslas Bourdin • CO-050 • CO-050 - Longitudinal follow-up of liver transplant recipients using intracellular tacrolimus concentrations and pharmacodynamics monitoring: preliminary results of the OPTILTH study > F. Florian LEMAITRE • CO-051 • CO-051 - Efficacy of ceftobiprole for Pseudomonas aeruginosa hospital-acquired pneumonia in critically ill patients: a pharmacokinetic-pharmacodynamic evaluation > C. Camille MANÉ • CO-052 • CO-052 - Pharmacokinetics of Hydroxychloroquine in childhood-onset systemic lupus erythematosus > N. Noël ZAHR • CO-053 • CO-053 - Development of a free online platform for personalized antibiotherapy: Pythi-A > R. Ronan Bellouard • CO-054 • CO-054 - PKPD relationship assessment of post-MA Dabrafenib plus Trametinib combo in patients with metastatic BRAFV600mut melanoma > L. Lauriane Goldwirt • CO-055 • CO-055 - Population pharmacokinetics and pharmacodynamics of ganciclovir in children undergoing hematopoietic stem cell transplantation > N. Naïm Bouazza • CO-056 • CO-056 - Characterizing adherence profiles based on C0 monitoring in kidney transplant patients: illusion or reality? > C. Caroline MONCHAUD • CO-057 • CO-057 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC > S. Stephane Bouchet